Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life

Abstract

To the editor: In their recommendations for diagnosis and treatment of the myelodysplastic syndromes (MDS),[1][1] the European Leukemia Net point out the crucial role of quality of life (QoL) assessment, as affected patients are most often elderly and have a largely incurable disease. We agree that